Login to Your Account



Financings Roundup

Anthera Approaches Phase III, Prices $40M Public Offering

By Catherine Shaffer
Staff Writer

Monday, January 28, 2013
With launch of its Phase III registration studies for Lupus drug blisibimod imminent, Anthera Pharmaceuticals Inc., of Hayward, Calif., priced an underwritten public offering worth $40 million in gross proceeds to support operations as it goes forward.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription